DYNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Dyne Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$15.23+0.98 (+6.88%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Dyne Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Dyne Therapeutics | Industry median |
|---|---|---|
| Market Cap | $2.84B | $166.30M |
| Enterprise Value | $1.95B | $88.19M |
| PB Ratio | 4.05 | 2.03 |
| P/TBV Ratio | 4.05 | 2.29 |
Income (trailing twelve months)
| Measure | Dyne Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$536.96M | -$21.40M |
| Net Income | -$519.41M | -$22.46M |
| EBITDA | -$534.79M | -$16.91M |
Returns
| Measure | Dyne Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -81.6% | -53.2% |
| Return on Assets (ROA) | -60.3% | -40.9% |
| Return on Capital Employed (ROCE) | -58.6% | -38.1% |
Balance sheet
| Measure | Dyne Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $898.48M | $61.43M |
| Net Cash (Debt) | $898.48M | $15.35M |
| Net Cash Per Share | $4.81 | $0.66 |
| Equity (Book Value) | $702.15M | $49.09M |
| Book Value Per Share | $3.76 | $1.37 |
| Tangible Book Value | $702.15M | $23.52M |
| Working Capital | $859.86M | $76.81M |
Financial position
| Measure | Dyne Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 12.02 | 3.34 |
| Quick Ratio | 11.51 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Dyne Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$477.82M | -$12.35M |
| Capital Expenditures | -$2.61M | -$1.08M |
| Free Cash Flow | -$480.43M | -$20.22M |
| FCF Per Share | -$2.57 | -$0.42 |
Efficiency
| Measure | Dyne Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$2.01M | -$703.34K |
| Employee Count | 258 | 74 |
Dividends and yields
| Measure | Dyne Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -18.3% | -23.3% |
| FCF Yield | -16.9% | -8.72% |
| Buyback Yield | 0.00% | -0.59% |
| Shareholder Yield | 0.00% | 0.00% |
Shares
| Measure | Dyne Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 186,746,000 | 58,127,000 |
| Shares Change (QoQ) | 0.28% | 0.54% |
| Float | 176,787,000 | 49,136,700 |
| Shares Held by Insiders | 5.33% | 11.6% |
| Shares Held by Institutions | 102.1% | 59.4% |
Scores
| Measure | Dyne Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 2.71 | -0.22 |
Calculated by StockData from Dyne Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.